Efficacy: remission (categorical) YMRS ≤ 12 and no increase in MADRS at end of study · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Efficacy: response (categorical) YMRS/SADS‐C decrease ≥ 50% by end of study · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Efficacy: remission (categorical) YMRS ≤ 12 and no increase in MADRS at end of study · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Efficacy: response (categorical) YMRS change ≥ 50% from baseline to end of study · acute mania
It is very uncertain whether lithium changes efficacy: response (categorical) YMRS decrease by ≥ 50% by end of… compared with quetiapine (very low certainty).
1 finding from 1 review
Remission · acute mania
Lithium showed no clear difference in efficacy: remission (categorical) Decrease in YMRS ≤ 12 by end of… compared with quetiapine (low certainty).
1 finding from 1 review
Remission · acute mania
Lithium leads to higher efficacy: remission (categorical) YMRS < 12 at end of study compared with placebo (high certainty).
1 finding from 1 review
Efficacy: response (categorical) MSRS/YMRS ≥ 50% decrease in score by end of study · acute mania
Lithium probably leads to lower efficacy: response (categorical) MSRS/YMRS ≥ 50% decrease in score… compared with olanzapine (moderate certainty).
1 finding from 1 review
Remission · acute mania
Lithium showed no clear difference in efficacy: remission (categorical) YMRS ≤ 12 at end of study compared with olanzapine (low certainty).
1 finding from 1 review
Efficacy: response (categorical) MSRS/YMRS ≥ 50% decrease in score by end of study · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Remission · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Efficacy: response (categorical) MSRS/YMRS ≥ 50% decrease in score by end of study · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Remission · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Efficacy: response (categorical) BMRS change ≥ 50% from baseline to end of study · acute mania
It is very uncertain whether lithium changes efficacy: response (categorical) BMRS change ≥ 50% from baseline to… compared with zuclopenthixol (very low certainty).
1 finding from 1 review
Remission · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Efficacy: response (categorical) BMRS change ≥ 50% from baseline to end of study · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Efficacy: remission (categorical) YMRS ≤ 12/absence of DSM‐IV mania by end of study · acute mania
Lithium showed no clear difference in efficacy: remission (categorical) YMRS ≤ 12/absence of DSM‐IV mania… compared with risperidone (low certainty).
1 finding from 1 review
Efficacy: response (categorical) BMRS change ≥ 50% from baseline to end of study · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Remission · acute mania
Lithium showed no clear difference in efficacy: remission (categorical) YMRS ≤ 12 at end of study compared with aripiprazole (moderate certainty).
1 finding from 1 review
Efficacy: response (categorical) YMRS change ≥ 50% from baseline to end of study · acute mania
Lithium leads to higher efficacy: response (categorical) YMRS change ≥ 50% from baseline to… compared with topiramate (high certainty).
1 finding from 1 review
Remission · acute mania
Lithium leads to higher efficacy: remission (categorical) YMRS ≤ 12 at end of study compared with topiramate (high certainty).
1 finding from 1 review